Company profile

Benitec Biopharma Inc.

Pipeline1 asset

BB-301BB-301 / PABPN1 / AAV ddRNAi silence-and-replace genetic medicine / Rare disease; neuromuscular
Oculopharyngeal muscular dystrophy (OPMD)Phase 1b/2aClinical-stage

Latest news7 items

May 14, 2026

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

Presentation / Abstract • Phase 1ASGCT oral presentation Fri, May 15, 2026, 8:00 AM EDT

Apr 28, 2026

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Presentation / Abstract • Phase 1/2

Mar 10, 2026

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

Presentation / Abstract • Phase 1

Mar 9, 2026

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Interim Data • Phase 1/2

Feb 23, 2026

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Presentation / Abstract • Phase 1/2

Feb 12, 2026

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

Interim Data • Phase 1/2

Jan 11, 2026

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Interim Data • Phase 1/2

Benitec Biopharma Inc. • Endpoint Arena